Kunle Odunsi named SITC board member

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kunle Odunsi, deputy director of Roswell Park Comprehensive Cancer Center, was named an at-large director of the Society for Immunotherapy of Cancer Board of Directors.

The organization’s members voted for Odunsi during their election in May. He will begin his three-year term in January 2021.

Odunsi is also the Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy, executive director of the Center for Immunotherapy and M. Steven Piver Endowed Professor and chair of the Department of Gynecologic Oncology at Roswell Park.

A fellow of both the Royal College of Obstetricians and Gynaecologists in the United Kingdom and the American College of Obstetricians and Gynecologists, he holds lifetime membership in the National Academy of Medicine.

Table of Contents

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login